Special Issue

Vaccines and Cancer Immunology

Message from the Guest Editors

This Special Issue aims to address the knowledge gap in the uses, mechanisms, efficacy, and adverse events of the developed or still-in-development vaccines for preventive and/or therapeutic uses in cancer; or non-cancer vaccines affecting cancer immunology or prognosis. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Cancer vaccines in clinical practice
- Cancer vaccine basic science and immunology
- The effect of non-cancer vaccines on the clinical course of cancers

We look forward to receiving your contributions.

Guest Editors

Dr. Abdelrahman Makram

School of Public Health, Imperial College London, London, UK

Dr. Nguyen Tien Huy

- 1. School of Tropical Medicine and Global Health, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
- 2. Institute of Research and Development, Duy Tan University, Da Nang, Vietnam

Deadline for manuscript submissions

closed (10 April 2024)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/157490

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

